From a clinical perspective of the treatment of BRAF‐mutated melanomas, this synergism could be exploited with either immune‐checkpoint modulators (Anti‐PD1 Ab or Anti CTLA‐4) (Postow et al, 2015) or with approaches based on adoptively transferred antitumor lymphocytes (Kwong et al, 2013). This evidence concerns the gene CTLA4 and melanoma.